Without a doubt, wet age-related macular degeneration (AMD) has been a lucrative market for companies. Regeneron Pharmaceuticals Inc. announced $1.2 billion in U.S. sales of Eylea (aflibercept) in the first half of 2015, and Roche AG posted CHF769 million (US$804 million) in U.S. sales of Lucentis (ranibizumab).